S-1/A: Lifeward Ltd. Files S-1/A for Public Offering to Bolster Operations Amidst Going Concern Doubts

Sentiment:

Securities Offering Prospectus 25 June 2025 7:00 AM

Lifeward Ltd., a medical device company, has filed an S-1/A registration statement to offer up to 4 million ordinary shares and accompanying warrants, seeking to raise approximately $3.6 million in net proceeds to fund ongoing commercial efforts and general corporate purposes, while acknowledging substantial doubt about its ability to continue as a going concern.

Delay expectedThe exercisability of the Warrants is contingent upon obtaining Warrant Shareholder Approval, which means there could be a delay in the full realization of the benefits from the offering if this approval is not secured promptly.If shareholder approval is not obtained at the first meeting, the company commits to calling a shareholder meeting every ninety (90) days thereafter until approval is received or the Warrants are no longer outstanding, indicating a potential prolonged period of uncertainty for warrant holders.

Capital raiseThe company is offering up to 4,000,000 ordinary shares and accompanying warrants.Pre-funded warrants are also being offered to certain purchasers, allowing them to acquire ordinary shares at a nominal exercise price of $0.0001.Placement Agent Warrants to purchase up to 240,000 ordinary shares will be issued as compensation to H.C. Wainwright & Co., LLC.The assumed combined public offering price for ordinary shares and accompanying warrants is $1.07, aiming for estimated net proceeds of approximately $3.6 million (assuming maximum sale and no warrant exercise).

Worse than expectedThe document explicitly states that the company has an accumulated deficit of approximately $269.7 million as of March 31, 2025.The company's independent registered public accounting firm included an explanatory paragraph in its report stating 'substantial doubt existed about our ability to continue as a going concern' as of December 31, 2024, and management concluded the same as of March 31, 2025.The offering is on a 'reasonable best efforts' basis with no minimum, meaning the actual proceeds raised may be 'substantially less than the maximum amount,' which could impede the company's ability to meet its obligations and business goals.

Summary

Lifeward Ltd. is offering up to 4,000,000 ordinary shares, each accompanied by a warrant to purchase one ordinary share, at an assumed combined public offering price of $1.07 per share and warrant.
The offering also includes pre-funded warrants for purchasers whose ownership would exceed 4.99% (or 9.99% by election) of outstanding shares, with an exercise price of $0.0001 per share, also accompanied by warrants.
The warrants issued to purchasers will have an exercise price of $1.07 per share and will be exercisable upon shareholder approval or immediately if certain pricing conditions are met, expiring five years from the initial exercise date.
The company will also issue up to 240,000 placement agent warrants to H.C. Wainwright & Co., LLC, exercisable at $1.3375 per share (125% of the offering price) and expiring five years from the commencement of sales.
The offering is on a 'reasonable best efforts' basis, meaning there is no minimum amount of securities required to be sold, and actual proceeds may be substantially less than the maximum.
Lifeward estimates net proceeds of approximately $3.6 million, assuming the maximum sale of ordinary shares and accompanying warrants, and no exercise of warrants, after deducting placement agent fees and estimated offering expenses.
The company reported an accumulated deficit of approximately $269.7 million as of March 31, 2025, and its financial statements include an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern.
Lifeward's product portfolio includes ReWalk Personal and Rehabilitation Exoskeletons for spinal cord injury, ReStore Exo-Suit for stroke rehabilitation, and AlterG Anti-Gravity systems (acquired August 2023).
The company received FDA clearance in March 2023 for ReWalk Personal Exoskeleton with stair and curb functionality and submitted a 510(k) for the ReWalk 7 Personal Exoskeleton in June 2024.
A strategic agreement was announced in March 2025 with CorLife, LLC, making them the exclusive distributor for the ReWalk Personal Exoskeleton in the workers compensation market.
Development of the ReBoot personal soft exo-suit for post-stroke individuals, which received Breakthrough Device Designation in November 2021, was paused in 2023 and remains on hold pending further evaluation.

Sentiment

Score: 4

Explanation: The sentiment is cautious due to the explicit 'going concern' warning and significant accumulated deficit. While the capital raise is a positive step to address financial needs and support operations, the 'reasonable best efforts' nature of the offering introduces uncertainty regarding the actual funds to be raised. The company is in a challenging financial position, and this offering is primarily for sustenance rather than aggressive growth.

Positives

The company is actively seeking to raise capital to support its ongoing commercial efforts, working capital, and general corporate purposes.
Recent FDA clearance for ReWalk Personal Exoskeleton with stair and curb functionality expands product utility and market access.
The submission of a 510(k) for the next-generation ReWalk 7 Personal Exoskeleton indicates continued product innovation.
The acquisition of AlterG in August 2023 diversified the product portfolio with Anti-Gravity systems, expanding reach to over 4,000 facilities globally.
The exclusive distribution agreement with CorLife, LLC is expected to increase penetration of SCI Products into the workers compensation market and facilitate claims processing.

Negatives

The company has an accumulated deficit of approximately $269.7 million as of March 31, 2025.
There is substantial doubt about the company's ability to continue as a going concern, as stated in its financial statements and by its independent auditors.
The offering is on a 'reasonable best efforts' basis with no minimum, meaning the actual capital raised could be significantly less than the maximum target, potentially hindering business objectives.
New investors will experience immediate dilution of $0.08 per share in net tangible book value.
The exercisability of the warrants is contingent upon shareholder approval, and if not obtained, the warrants may have no value.
There is no established public trading market for the Warrants or Pre-Funded Warrants, limiting their liquidity.
The company has no current plans to pay cash dividends in the foreseeable future.
Development of the ReBoot personal soft exo-suit, a product with Breakthrough Device Designation, has been paused since 2023.

Risks

Substantial doubt exists regarding the company's ability to continue as a going concern, potentially leading to insolvency and loss of investment.
The company will require additional capital funding, and future equity issuances may cause substantial dilution to existing shareholders.
The 'reasonable best efforts' nature of the offering means the company may not raise sufficient capital to meet its operational needs or business goals.
Management has broad discretion over the use of offering proceeds, which may not always improve operating results or enhance share value.
The exercisability of the Warrants is contingent on shareholder approval, which may not be obtained, rendering the Warrants valueless.
Future equity offerings or other equity issuances will cause further dilution to ownership interests.
Future sales of ordinary shares, or the perception of such sales, could cause the share price to decline.
Purchasers entering into securities purchase agreements may have rights superior to other investors, potentially creating an uneven playing field.
The absence of a public trading market for Warrants and Pre-Funded Warrants limits their liquidity.
Holders of Warrants and Pre-Funded Warrants have no shareholder rights until exercise, except as specifically provided.
The Warrants and Pre-Funded Warrants are speculative in nature, and there is no assurance the ordinary share price will exceed their exercise price.
The market price and trading volume of the company's ordinary shares may be highly volatile due to various factors, including company performance, industry trends, and market sentiment.
Risks related to cybersecurity attacks or incidents on IT systems and data.
Challenges in maintaining and growing market acceptance of products and achieving reimbursement from third-party payors.
Difficulties in integrating acquired operations (e.g., AlterG) and realizing anticipated benefits.
Dependence on third-party suppliers for components and manufacturers for production.
Risks associated with compliance with medical device reporting regulations and maintaining regulatory approvals.
Potential for infringement of intellectual property rights of others or inability to protect the company's own IP.
Impact of substantial sales of shares by certain shareholders on the market price.
Exposure to broader market and economic conditions, including inflationary pressures, interest rate fluctuations, and global instability (e.g., Russia-Ukraine conflict, Middle East conflict, China-Taiwan tensions).

Future Outlook

Lifeward Ltd. intends to use the net proceeds from this offering for continuing commercial efforts, working capital, and general corporate purposes. The company will continue to evaluate other products for distribution or acquisition to broaden its offerings. It is committed to seeking shareholder approval for the issuance of ordinary shares upon exercise of the warrants, holding meetings every 90 days if initial approval is not obtained, until approval is secured or the warrants are no longer outstanding.

Management Comments

Management believes their relationships with employees are good.
Management concluded that substantial doubt about the company's ability to continue as a going concern exists as of the date of the issuance of these financial statements.

Industry Context

Lifeward Ltd. operates in the medical device industry, specializing in physical rehabilitation and recovery. The company's focus on robotic exoskeletons (ReWalk) and anti-gravity systems (AlterG) positions it within the growing market for assistive and rehabilitative technologies. Its expansion through distribution agreements, such as with CorLife for the workers' compensation market, and strategic acquisitions like AlterG, indicates a strategy to broaden its product offerings and market penetration. The pause in development for the ReBoot device highlights the challenges and strategic decisions involved in R&D within this capital-intensive sector.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The company's Articles of Association require the board of directors to consist of not less than five but no more than thirteen directors, including two external directors as and if required by Israeli Companies Law.	NA	Provides a framework for board composition and size, ensuring a minimum number of directors and flexibility up to thirteen. The requirement for external directors is subject to Israeli law and the company's election to opt out.
External Director Requirement	The company opted out of the requirement to have external directors in February 2018, as permitted by regulations under the Israeli Companies Law for companies without a controlling shareholder that comply with U.S. securities laws and Nasdaq corporate governance rules.	February 2018	Reduces a specific corporate governance burden imposed by Israeli law, aligning more closely with U.S. corporate governance practices for public companies without a controlling shareholder. This may affect board independence from an Israeli regulatory perspective but is compliant with Nasdaq rules.
Director Removal/Amendment of Staggered Board Provisions	Removal of any director (other than external directors) or amendment of staggered board provisions requires a 65% vote of total voting power of shareholders.	NA	Provides a higher threshold for significant governance changes related to board composition, potentially enhancing board stability and making hostile takeovers more difficult.
Voluntary Winding Up/Scheme of Arrangement	Requires approval of holders of 75% of voting rights represented at the meeting and voting on the resolution.	NA	Establishes a high threshold for major corporate restructuring or dissolution, providing significant protection against such actions without broad shareholder consensus.
Shareholder Meeting Quorum	Quorum requires at least two holders present in person or by proxy, holding at least 33 1/3% of total outstanding voting rights.	NA	Sets a relatively low quorum requirement, making it easier to convene and conduct shareholder meetings.
Shareholder Voting	All shareholder resolutions require a simple majority vote, unless otherwise required by Israeli Companies Law or Articles of Association (e.g., certain related party transactions, director removal, winding up).	NA	Standardizes most voting requirements to a simple majority, promoting efficiency, but retains higher thresholds for critical corporate actions to protect shareholder interests.

Legal Proceedings

The company was previously involved in a securities class action litigation that was dismissed in full in November 2020.
No current action, suit, inquiry, notice of violation, proceeding or investigation pending or threatened against the company or its subsidiaries that would result in a Material Adverse Effect.

Related Party Transactions

None disclosed in the provided text beyond standard compensation for officers and directors (salary, consulting fees, expense reimbursement, equity-based compensation under share option and incentive plans), which are not in excess of $120,000 individually.

Stakeholder Impact

Shareholders: Face immediate and potential future dilution from the offering, and the value of their investment is at risk due to the company's going concern doubts and market volatility. No cash dividends are planned.
Employees: The company's ability to continue as a going concern directly impacts job security. No imminent labor disputes are reported, suggesting stable employee relations.
Customers: The capital raise is intended to support continuing commercial efforts and product development, which could benefit customers through ongoing product availability and innovation.
Suppliers: The company's financial health and ability to meet obligations are critical for maintaining relationships with suppliers, especially given the need for components from third-party suppliers.
Creditors: The company's 'going concern' warning indicates a risk to creditors, as its ability to meet existing and expected obligations is in doubt without additional financing.

Next Steps

Lifeward Ltd. will continue its commercial efforts, utilize proceeds for working capital, and general corporate purposes.
The company will seek shareholder approval for the issuance of ordinary shares upon exercise of the Warrants.
If initial shareholder approval for warrants is not obtained, the company will call subsequent shareholder meetings every 90 days until approval or warrants are no longer outstanding.
The company will continue to evaluate other products for distribution or acquisition to expand its offerings.
The company will maintain the listing of its ordinary shares on The Nasdaq Capital Market and apply to list all newly issued shares and warrant shares.

Key Dates

Date	Description
2001	Company incorporated under the laws of the State of Israel.
November 2021	ReBoot received Breakthrough Device Designation from the FDA.
March 2023	Received FDA clearance for ReWalk Personal Exoskeleton with stair and curb functionality.
August 2023	Acquired AlterG, a provider of Anti-Gravity systems.
December 31, 2024	Ceased operations at offices in Fremont, California and Queens, New York.
January 8, 2025	Warrants from January 2025 private placement issued, exercisable until January 10, 2028.
March 2025	Announced agreement with CorLife, LLC for exclusive distribution of ReWalk Personal Exoskeleton in the workers compensation market.
March 31, 2025	Company had an accumulated deficit of approximately $269.7 million and net tangible book value of $10.9 million.
June 2024	Submitted 510(k) premarket notification for ReWalk 7 Personal Exoskeleton device to the FDA.
June 18, 2025	Official closing price of ordinary shares on The Nasdaq Capital Market was $1.07.
June 19, 2025	11,602,266 ordinary shares outstanding.
June 25, 2025	Date of S-1/A filing.
July 2, 2025	Expiration date for certain warrants issued in July 2020 private placement.
July 30, 2025	Scheduled termination date for the current offering, unless terminated earlier by the company.
December 30, 2025	Expiration date for warrants granted on December 31, 2015, and December 28, 2016, to Kreos Capital V (Expert Fund) Limited.
January 6, 2026	Expiration date for certain warrants issued in July 2020 private placement.
June 8, 2026	Expiration date for warrants issued in December 2020 private placement.
August 26, 2026	Expiration date for warrants issued in February 2021 private placement.
September 27, 2026	Expiration date for certain warrants issued in September 2021 private placement.
March 29, 2027	Expiration date for certain warrants issued in September 2021 private placement.
January 10, 2028	Expiration date for warrants issued in January 2025 private placement.

Recommendation

hold

Keywords

Lifeward Ltd., SEC Filing, S-1/A, Securities Offering, Ordinary Shares, Warrants, Pre-Funded Warrants, Capital Raise, Medical Devices, Rehabilitation, Exoskeleton, ReWalk, ReStore, AlterG, Going Concern, Dilution, Nasdaq, H.C. Wainwright & Co., Corporate Finance, Investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.